PriceTargets.com logo

Beauty Health - SKIN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $2.55
  • Forecasted Upside: 74.66%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.46 As of 12/20/2024 06:16 PM ET
▲ +0.045 (3.18%)

This chart shows the closing price for SKIN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Beauty Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SKIN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SKIN

Analyst Price Target is $2.55
▲ +74.66% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Beauty Health in the last 3 months. The average price target is $2.55, with a high forecast of $5.00 and a low forecast of $1.00. The average price target represents a 74.66% upside from the last price of $1.46.

This chart shows the closing price for SKIN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 polled investment analysts is to hold stock in Beauty Health. This rating has held steady since October 2024, when it changed from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 3 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2024Canaccord Genuity GroupBoost TargetHold ➝ Hold$1.25 ➝ $1.75
8/12/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$2.00 ➝ $1.25
8/9/2024Piper SandlerReiterated RatingUnderweight ➝ Underweight$1.50 ➝ $1.00
7/26/2024Stifel NicolausLower TargetHold ➝ Hold$4.00 ➝ $2.00
7/11/2024Piper SandlerLower TargetUnderweight ➝ Underweight$2.50 ➝ $1.50
5/13/2024DA DavidsonReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/13/2024TD CowenLower TargetHold ➝ Hold$4.00 ➝ $3.00
5/10/2024Piper SandlerLower TargetUnderweight ➝ Underweight$3.00 ➝ $2.50
3/15/2024DA DavidsonReiterated RatingBuy ➝ Buy$5.00
3/14/2024Canaccord Genuity GroupBoost TargetHold ➝ Hold$3.00 ➝ $4.00
3/13/2024TD CowenBoost TargetMarket Perform ➝ Market Perform$2.50 ➝ $4.00
3/13/2024Stifel NicolausReiterated RatingHold ➝ Hold$3.00 ➝ $4.00
3/13/2024Piper SandlerReiterated RatingUnderweight ➝ Underweight$2.00 ➝ $3.00
2/29/2024Canaccord Genuity GroupBoost TargetHold ➝ Hold$2.50 ➝ $3.00
11/15/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
11/14/2023Stifel NicolausLower TargetHold ➝ Hold$8.00 ➝ $3.00
11/14/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$10.00 ➝ $2.50
11/14/2023JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
11/14/2023Canaccord Genuity GroupDowngradeBuy ➝ Hold$10.00 ➝ $2.50
11/14/2023Piper SandlerDowngradeOverweight ➝ Underweight$12.00 ➝ $2.00
11/14/2023TD CowenDowngradeOutperform ➝ Market Perform$9.00 ➝ $2.50
11/14/2023BenchmarkDowngradeBuy ➝ Hold
11/14/2023Raymond JamesDowngradeMarket Perform ➝ Underperform
11/14/2023William BlairDowngradeOutperform ➝ Market Perform
9/19/2023Imperial CapitalInitiated CoverageOutperform
9/13/2023BenchmarkReiterated RatingBuy ➝ Buy$23.00
8/25/2023Canaccord Genuity GroupReiterated RatingBuy$10.00
8/10/2023TD CowenLower TargetOutperform ➝ Outperform$15.00 ➝ $9.00
8/10/2023DA DavidsonLower TargetBuy ➝ Buy$35.00 ➝ $16.50
8/8/2023BenchmarkReiterated RatingBuy ➝ Buy$23.00
6/20/2023Stifel NicolausDowngradeBuy ➝ Hold$17.00 ➝ $10.00
6/15/2023Piper SandlerLower Target$17.00 ➝ $15.00
3/28/2023Canaccord Genuity GroupReiterated RatingBuy$18.00
3/20/2023BNP ParibasUpgradeUnderperform ➝ Neutral
3/14/2023BenchmarkReiterated RatingBuy$23.00
3/1/2023DA DavidsonBoost TargetBuy$32.00 ➝ $35.00
2/28/2023BenchmarkReiterated RatingBuy$23.00
2/16/2023CowenLower TargetOutperform$20.00 ➝ $15.00
12/16/2022Piper SandlerLower Target$16.00 ➝ $15.00
11/23/2022The Goldman Sachs GroupLower TargetBuy$22.00 ➝ $19.00
11/15/2022DA DavidsonBoost Target$32.00
11/9/2022DA DavidsonBoost TargetBuy$31.00 ➝ $32.00
11/9/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$22.00 ➝ $11.00
9/28/2022DA DavidsonBoost TargetBuy$30.00 ➝ $31.00
9/16/2022JPMorgan Chase & Co.Boost Target$18.00 ➝ $22.00
9/16/2022Piper SandlerBoost TargetOverweight$20.00 ➝ $23.00
9/16/2022DA DavidsonBoost TargetBuy$25.00 ➝ $30.00
8/16/2022The Goldman Sachs GroupLower TargetBuy$25.00 ➝ $22.00
8/10/2022Piper SandlerLower TargetOverweight$22.00 ➝ $20.00
8/10/2022DA DavidsonBoost TargetBuy$24.00 ➝ $25.00
7/8/2022Piper SandlerLower TargetOverweight$24.00 ➝ $22.00
6/30/2022Canaccord Genuity GroupLower Target$22.00 ➝ $20.00
5/11/2022Canaccord Genuity GroupLower Target$27.00 ➝ $22.00
5/11/2022DA DavidsonLower Target$35.00 ➝ $24.00
5/11/2022Piper SandlerLower Target$26.00 ➝ $24.00
4/28/2022Piper SandlerLower Target$31.00 ➝ $26.00
3/14/2022BenchmarkBoost TargetBuy$18.00 ➝ $23.00
3/11/2022JPMorgan Chase & Co.Initiated CoverageOverweight$24.00
2/23/2022DA DavidsonBoost TargetBuy$32.00 ➝ $35.00
1/7/2022William BlairInitiated CoverageOutperform
12/23/2021Raymond JamesInitiated CoverageMarket Perform
11/10/2021DA DavidsonBoost TargetBuy$26.00 ➝ $32.00
10/7/2021Stifel NicolausInitiated CoverageBuy$33.00
10/4/2021CowenInitiated CoverageOutperform$32.00
9/1/2021Piper SandlerBoost TargetSell ➝ Overweight$27.00 ➝ $33.00
8/11/2021DA DavidsonBoost TargetBuy$17.50 ➝ $26.00
8/11/2021BenchmarkBoost TargetBuy$18.00 ➝ $25.00
7/19/2021Jefferies Financial GroupInitiated CoverageBuy$22.00
7/1/2021The Goldman Sachs GroupInitiated CoverageBuy$31.00
6/28/2021BenchmarkBoost TargetBuy$16.00 ➝ $22.00
6/24/2021Piper SandlerInitiated CoverageOverweight$24.00
6/1/2021DA DavidsonBoost TargetBuy$16.00 ➝ $17.50
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.87 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 68 very positive mentions
  • 37 positive mentions
  • 7 negative mentions
  • 3 very negative mentions
Mentions as of
5/25/2024
  • 13 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 9 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 68 very positive mentions
  • 30 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 42 very positive mentions
  • 24 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2024
  • 39 very positive mentions
  • 24 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 34 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 31 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 31 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Beauty Health logo
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
Read More

Today's Range

Now: $1.46
Low: $1.39
High: $1.48

50 Day Range

MA: $1.58
Low: $1.40
High: $1.85

52 Week Range

Now: $1.46
Low: $0.91
High: $5.17

Volume

916,727 shs

Average Volume

1,746,180 shs

Market Capitalization

$181.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Beauty Health?

The following Wall Street research analysts have issued research reports on Beauty Health in the last twelve months: Canaccord Genuity Group Inc., DA Davidson, Piper Sandler, Stifel Nicolaus, and TD Cowen.
View the latest analyst ratings for SKIN.

What is the current price target for Beauty Health?

0 Wall Street analysts have set twelve-month price targets for Beauty Health in the last year. Their average twelve-month price target is $2.55, suggesting a possible upside of 74.7%. DA Davidson has the highest price target set, predicting SKIN will reach $5.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $1.00 for Beauty Health in the next year.
View the latest price targets for SKIN.

What is the current consensus analyst rating for Beauty Health?

Beauty Health currently has 1 sell rating, 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SKIN, but not buy more shares or sell existing shares.
View the latest ratings for SKIN.

What other companies compete with Beauty Health?

Other companies that are similar to Beauty Health include Butterfly Network, Iradimed, AxoGen, Semler Scientific and SI-BONE. Learn More about companies similar to Beauty Health.

How do I contact Beauty Health's investor relations team?

Beauty Health's physical mailing address is 1819 West Avenue Bay 2, Miami Beach FL, 33139. The company's listed phone number is 800-603-4996 and its investor relations email address is https://investors.beautyhealth.com. The official website for Beauty Health is hydrafacial.com. Learn More about contacing Beauty Health investor relations.